Published on
March 4, 2024
- 14:00 GMT
AvantGen Receives Milestone Payment for First Patient Dosed in Phase 1 Study with Kite’s Investigational CAR-T Therapy
SAN DIEGO, CA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- AvantGen Inc., a leader in antibody discovery and engineering, announced today that it has received the first milestone payment from Kite, a Gilead Company, for the achievement of the …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
